Expanding Clinical Pipelines, Contract Manufacturing Adoption, and Automation-Led Process Innovation Fuel Robust Market Growth Globally.Austin, United States, Feb. 27, 2026 (GLOBE NEWSWIRE) -- ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...
CAPEX investment for setting up the PERC production is higher in the case of a MLD setup. Image: Fraunhofer ISE A solar cell manufacturing plant can reduce water consumption by up to 79% with existing ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
History is coming full circle as induced pluripotent stem (iPS) cell-derived cell therapy maker Shinobi Therapeutics links up with Panasonic and Japan’s Kyoto University, where the first mouse iPS ...
A German team developed models to illustrate water-saving potential in PERC silicon solar cell manufacturing based on a circular approach and commercially available technology. In the case of a 5 GW ...
The global market for N-TOPCon Cells was valued at USD 10020 Million in the year 2024 and is projected to reach a revised size of U ...
Solar cell photovoltaic research, development, and manufacturing continue to rapidly move forward with new advances in solar texture and metallization manufacturing leading to higher efficiency solar ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results